We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AutoGenomics Develops Tests in Personalized Medicine

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AutoGenomics Develops Tests in Personalized Medicine "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

AutoGenomics has announced that it has released a series of pharmacogenetic ASRs including CYP 450 2C9 / VKORC1 that can be used to assess Warfarin sensitivity.

Other ASR applications include CYP 450 2D6, 2C19, NAT2, UGT1A1, MDR1, 3A4/3A5 tests.

Says Fareed Kureshy, CEO of AutoGenomics, "This perhaps is the most comprehensive panel of ASRs made available by any company and poises AutoGenomics to be the leader in the now emerging era of personalized medicine."

Milton Drachenburg, M.D., Medical Director, Hematology at Long Beach Memorial Medical Center, one of AutoGenomics' expanding base of customers, says, "We currently offer genetic tests to our clinicians to assess inherited disposition to hypercoagulability."

"We anticipate that future tests could also help clinicians understand why patients respond differently to medications."

The company has submitted an application to the FDA for 510(k) clearance for an automated multiplexing microarray platform that can provide amplified samples to test results without manual intervention by the operator.